InspireMD Q4 revenue rises 62%, beats estimates

InspireMD

18/03/2026 11:13

Overview

Carotid stent developer's Q4 revenue grew 62% yr/yr, beating analyst expectations

Q4 operating loss and net loss were lower than analysts' forecasts

Revenue growth driven by U.S. launch of CGuard Prime and rising international demand

Outlook

InspireMD expects 2026 revenue between $13 mln and $15 mln, up 45%-65% over 2025

Company sees continued momentum in U.S. and international demand for CGuard platform

Approval for TCAR indication could expand U.S. market opportunity, pending FDA decision

Result Drivers

U.S. SALES - U.S. revenue rose 74% sequentially, driven by CGuard Prime

INTERNATIONAL DEMAND - International revenue rose due to increased penetration of key markets with CGuard

HIGHER OPERATING EXPENSES - Operating expenses increased due to greater headcount and investment to support U.S. commercial launch

Company press release: ID:nGNXb9PBxm

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$3.15 mln
$2.63 mln (3 Analysts)
Q4 Net Income
Beat
-$11.76 mln
-$15.003 mln (3 Analysts)
Q4 Income From Operations
Beat
-$12.08 mln
-$15.14 mln (3 Analysts)
Q4 Basic EPS
-$0.14
Q4 Gross Profit
$1.18 mln
Q4 Operating Expenses
$13.26 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for InspireMD Inc is $5.00, about 179.3% above its March 17 closing price of $1.79

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)